Noven, P&G partner on HSDD patches for women

MIAMI Noven Pharmaceuticals and Procter & Gamble Pharmaceuticals will develop and commercialize a line of patches to treat hypoactive sexual desire disorder in women, Noven announced Wednesday.

Under the agreement, P&G’s pharmaceutical division will have an exclusive worldwide license to the prescription testosterone patches, as well as for potential next-generation patches for treating HSDD. In return, Noven will receive royalties, and P&G will fund clinical development costs and be responsible for regulatory filings and marketing applications.

The patches use Noven’s DOT Matrix transdermal delivery technology.

HSDD is a form of sexual dysfunction that affects women, resulting in low sexual desire leading to personal distress. The Food and Drug Administration has not approved any products to treat HSDD, though P&G’s testosterone patch Intrinsa has been approved in some other countries for treating the condition.